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Background: Serum proﬁling using mass spectrometry-based proteomic techniques has great potential to detect
biomarkers that might improve the management for advanced breast cancer patients. The albuminome has
previously been investigated as a tool in biomarker discovery, however other high abundant blood proteins
are also likely to sequester potentially interesting molecules.
Methods: Afﬁnity resin puriﬁed and isolated Transferrin and associated bound proteins from normal control and
breast cancer patient serum samples were analysed by label-freemass spectrometry during the discovery phase.
Results: 21 signiﬁcant proteins were identiﬁedwith Fibrinogen and Fibronectin selected for further analysis in an
independent sample set, with signiﬁcant difference foundwhen comparing the controls groups (normal healthy
control, inﬂammatory bowel disease and benign breast disease) to stage IV breast cancer.
Conclusions: The area under the curve value for Fibrinogen compared favourably with cancer antigen 15-3, an
established breast cancer tumour marker. A combination of all three biomarkers improved accuracy when com-
paring control/benign to stage IV breast cancer patient groups.
General signiﬁcance:Mass spectrometry proﬁling of Transferrin-bound proteins has revealed serum proteins that
can distinguish between serum from advanced breast cancer patients and healthy control subjects with high
conﬁdence.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Breast cancer is a very common disease that affects approximately 1
in 8 women at some point in their lives [1]. Breast cancer is commonly
treated by various combinations of surgery, radiation therapy, chemo-
therapy, and hormone therapy with prognosis and selection of therapy
inﬂuenced by clinical and pathology features [2]. In recent years, there
has been a signiﬁcant improvement in the understanding of molecular
events and critical pathways involved in breast cancer. This has led to
the identiﬁcation of novel targets and development of anticancer thera-
pies referred to as targeted therapy [3,4].
In breast cancer care, three tumour markers, cancer antigen 15-3
(CA 15-3), cancer antigen 27.29 (CA 27.29), and carcinoembryonic anti-
gen (CEA) have been used to help monitor advanced disease [5–7].ational University of Ireland,
806368; fax: +353 1 7083845.
. This is an open access article underHowever, like most circulating protein biomarkers, they suffer from
sub-optimum performance and more accurate molecules are needed,
alone or in combinationwith existing biomarkers [8]. Therefore, the im-
proved ability to monitor malignancy in the blood from breast cancer
patients using biomarkers may be helpful for determining response to
treatments in the future.
The discovery of clinically relevant cancer biomarkers using mass
spectrometry (MS)-based proteomics has proven difﬁcult, primarily be-
cause of the enormous dynamic range of blood-derived protein concen-
trations and the fact that the 22 most abundant blood-derived proteins
constitute approximately 99% of the total serumproteinmass [9].While
most strategies focus on removing or diluting such high abundant pro-
teins, some studies have evaluated this protein group as a potential
source of diagnostic material, with a particular emphasis on proteins,
protein fragments or peptides that interact with this high abundance
group [10].
Previous work performed on the analysis of high abundant protein
cargo has focused on Albumin, as this protein accounts for more thanthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Clinicopathologic features of the normal healthy control and breast cancer patient samples
used for proteomic analysis of Transferrin-associated proteins (discovery set) with subse-
quent analysis of signiﬁcant proteins in larger numbers (validation set).
Discovery Set n Validation Set n
Normal healthy control Normal healthy control
No. cases 10 No. cases 54
Age (average ± standard
deviation)
51 ± 11 Age (average ± standard
deviation)
52 ± 9
Breast cancer Inﬂammatory bowel disease
No. cases 10 No. cases 19
Age (average ± standard
deviation)
56 ± 10 Age (average ± standard
deviation)
44 ± 8
Tumour stage
IV 10 Benign breast disease
Type No. cases 12
Invasive lobular carcinoma 2 Age (average ± standard
deviation)
43 ± 20
Invasive ductal carcinoma 8
Breast cancer
No. cases 155
Age (average ± standard
deviation)
55 ± 12
Tumour stage
I 20
II 20
III 39
IV 76
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drugs, proteins, hormones and other chemicals,withmanyof these likely
to be released directly from diseased tissue [11–13]. High abundant
proteins sequestering other cargo proteins help to increase their abun-
dance and at the same time protecting them from being eliminated by
the body, therefore facilitating their detection in biomarker discovery
analysis.
Transferrin, likely Albumin, is a high abundant serum protein and is
themajor iron-binding protein, having a vital role in iron transport. Ad-
ditionally, Transferrin has many other uses including antimicrobial
functions and growth factor effects on mammalian cell proliferation
and differentiation [14]. This investigation centres on the analysis of
Transferrin-bound proteins from control and breast cancer patients
using resins to capture human serum Transferrin from blood samples.
Transferrin-bound proteins/peptides isolated using this method were
evaluated using label-free proteomic methods to identify differentially
expressed between control and breast cancer samples. A number of can-
didate biomarkers were identiﬁed, with many of these found to be in-
volved in the complement and coagulation cascades. Fibronectin and
ﬁbrinogenwere selected for further analysis in a larger cohort of patient
samples along with CA15-3, an established biomarker in breast cancer.
All these molecules were found to be signiﬁcantly altered in patient
serum samples highlighting the usefulness of analysing the high-
abundant fraction associated proteins.Type
Invasive lobular carcinoma 16
Invasive ductal carcinoma 1392. Materials & methods
2.1. Patient information and sample collection
Samples were collected through a collaborative project involving
St Vincent's University Hospital, Dublin 4, Ireland, coordinated through
ICORG (the All Ireland Co-operative Oncology Research Group, www.
icorg.ie). The sampleswere collected according to standard phlebotomy
procedures from consented patients. Ethical consent was granted from
each of the respective Hospital Ethics Committees. A total of 10 ml of
blood was collected into additive free (serum) blood tubes and was
allowed to clot for 30 min to 1 h at room temperature. The serum was
denuded by pipette from the clot and poured into a clean tube. The
tubes were centrifuged at 1000 ×g for 30 min at 4 °C. Serum was
aliquoted in the cryovial tubes, labelled and stored at −80 °C until
time of analysis. The time from sample procurement to storage at
−80 °C was less than 3 h. Each serum sample underwent not more
than three freeze/thaw cycles prior to analysis. Table 1 provides a sum-
mary of the total number of patients analysed and a breakdown of their
clinicopathologic parameters.2.2. Transferrin isolation
CaptureSelect™ Transferrin Afﬁnity Matrix (Life Technologies
Corporation, USA) was used for the puriﬁcation and isolation of Transfer-
rin from normal control and breast cancer patient serum samples accord-
ing to the manufacturer's protocol.2.3. 1D gel electrophoresis
Protein quantiﬁcationwas performed using the Quick Start Bradford
Protein Assay (Biorad) using bovine serum albumin as a protein stan-
dard. 20 μg of protein was mixed with reducing buffer 1:1 (50 mM
Tris–HCl pH 6.8; 2% SDS; 10% glycerol; 1% β-mercaptoethanol;
12.5 mM EDTA; 0.02% bromophenol blue) and loaded onto NuPAGE®
12% Bis–Tris Gels (Invitrogen) and electrophoretically separated using
a MOS/SDS buffer according to the manufacturer's instructions and
stained with Coomassie Brilliant Blue R-250.2.4. Protein digestion
Isolated Transferrin and bound proteins were precipitated using ice-
cold acetone and resuspended in 8 M Urea with vortexing, sonication
and centrifugation. Volumes and the concentration of protein suspen-
sions were equalized and then reduced for 30 min with 10 mM DTT
and alkylated for 20 min in the dark with 25 mM iodoacetamide in
50 mM ammonium bicarbonate. The proteolytic digestion of proteins
was carried out in 2 steps. Firstly, digestion was performed with se-
quencing grade Lys-C at a ratio of 1:100 (protease/protein) for 4 h at
37 °C, followed by dilution with 4 times the initial sample volume in
50 mM ammonium bicarbonate. Secondly, further digestion was
based on incubation with sequencing grade trypsin at a ratio of 1:25
(protease/protein) overnight at 37 °C. The protease-treated serum pro-
tein suspensions were diluted 3:1 (v/v) with 2% triﬂuoroacetic acid in
20% acetonitrile to stop the reaction and subject to C18 clean-up prior
to mass spectrometry.2.5. Label-free LC–MS/MS analysis
The nano LC–MS/MS analysis of normal control and breast cancer
patient samples was carried out on an Ultimate 3000 nanoLC system
(Dionex UK, Camberley, United Kingdom) coupled to an LTQ Orbitrap
XL mass spectrometer (Thermo Fisher Scientiﬁc, Dublin, Ireland) in
the Proteomics Facility of theNational Institute for Cellular Biotechnology,
Dublin City University. The MS apparatus was operated in data-
dependent mode and externally calibrated. Survey MS scans were ac-
quired in the Orbitrap in the 300–2000 m/z range with the resolution
set to a value of 30 000 atm/z 400 and lockmass set to 445.120025 u. Pro-
cessing of the raw data generated from LC–MS/MS analysis was carried
out with Progenesis label-free LC–MS software (version 3.1; Non-Linear
Dynamics, Newcastle upon Tyne, UK). The retention times of all of the
other runs were aligned to this reference run and peak intensities were
thennormalised. The following criteriawere applied to assign a serumas-
sociated proteins as conﬁdently identiﬁed: (i) an ANOVA score between
experimental groups of ≤0.05, (ii) proteins with ≥1 peptides matched
and (iii) a MASCOT score N40.
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ELISA kits for Fibrinogen (EF1040-1) and for Fibronectin (EF1045-1)
from Assaypro were used as per manufacturer's instructions (AssayPro,
Winﬁeld,MO, USA). CA15-3was assayed using an ELISA kit fromAbcam
(ab108633, Abcam UK). Standard curves were prepared for each ELISA
kit and after completion of each assay, plates were read to determine
the optical density (absorbance) of each well by reading the plate
with the microplate reader (Bio-Tek instruments Inc., Vermont, USA)
set to 450 nm with a wavelength correction set to 570 nm. Duplicate
measurements were performed for each sample.
2.7. Statistical analysis
Student t-test was used to identify statistically signiﬁcant changes in
abundance levels for speciﬁc proteins between normal control and
breast cancer patient serum samples. The area under the curve (AUC)
was calculated to provide a summary of overall classiﬁer effectiveness
(MedCalc, version 13-0-0-0 64-bit, Medcalc Software, Mariakerke,
Belgium). For multivariate analysis of biomarker combinations, logistic
regression (LR) analysis of the serum biomarker levels in these patients
groups was performed.
3. Results
3.1. Proteomic proﬁling
Prior to label-free MS analysis, serum samples from normal control
and advanced breast cancer patients were used as bioﬂuids to isolate
Transferrin from using the CaptureSelect™ afﬁnity resin speciﬁcally de-
signed to capture Transferrin from complex samples such as serum
(Table 1 — Discovery set). Analysis of this fraction was visualised byFig. 1. SDS-PAGE analysis of Transferrin-associated proteins. Samples were electrophoretically
with ß-mercaptoethanol. Aliquots of 20 μg were loaded and the gel was stained with Coo
associated proteins from normal healthy control and breast cancer patient serum samples. The
by mass spectrometry. This band was identiﬁed as Transferrin (Mascot score 341).1D-gel electrophoresis and Coomassie blue staining of lane 1 —molecu-
lar weight standards, lanes 3–7 Transferrin and Transferrin-bound pro-
teins from normal control serum samples and lanes 8–12 Transferrin
and Transferrin-bound proteins from advanced breast cancer patient
serum samples (Fig. 1). The staining pattern reveals an abundant protein
at approximately 80 kDa, subsequently identiﬁed as Transferrin by mass
spectrometry (Mascot score: 341). Other noticeably weaker stained
bands are also visible, most likely representing proteins found to be
bound to Transferrin.
Afﬁnity resin isolated Transferrin and associated bound proteinswere
analysed by label-free MS analysis, an established powerful method for
peptide/protein quantitation. Progenesis LC–MS software was used to
compare normal control serum samples to advanced breast cancer pa-
tient samples. Proteins that were only identiﬁed by a single peptide
(the so-called “one-hit wonders”) were included in the protein list of
Transferrin-bound proteins (Table 2). STRING analysis was performed
to identify protein interactions and associations between the proteins
of interest [15,16],withKEGGanalysis used to detect enrichment of func-
tional systems for this network in STRING (Fig. 2). Of particular interest
from this protein analysis was the number of protein involved in the
complement and coagulation cascades, including FGG, FGA, FGB,
SERPINC1, C1QA, C1QB, C3, CFH, F2 and SERPINF2. Of these only 2, F2
and SERPINF2were found to have an elevated abundance level in normal
control individual serum samples compared to advanced breast cancer
patients.3.2. ELISA analysis of Fibrinogen, Fibronectin and CA15-3
ELISA analysis of Fibrinogen, Fibronectin and CA15-3 in serum sam-
ples was performed in normal healthy control (n = 54), inﬂammatory
bowel disease (n = 19), benign breast disease (n = 12), stage I breast
cancer (n = 20), stage II breast cancer (n = 20), stage III breast cancerseparated using a gradient (10–20%) polyacrylamide slab gel under reducing conditions
massie blue. Lane 1 — molecular weight standards; 3–12 Transferrin and Transferrin-
most intense band at approximately 80 kDa was cut from the gel, digested and analysed
Table 2
List of proteins found to be differentially expressed at statistically signiﬁcant levels (p ≤ 0.05, fold change ≥ 2) when comparing Transferrin-associated proteins in normal control
(n = 10) to stage IV breast cancer (n = 10) patient serum samples (Discovery sample set). Included in the table is the gene symbol count, c, protein identiﬁcation, peptide conﬁdence
score (Mascot), p-value, fold-change and highest/lowest mean change.
Gene name Protein identiﬁcation Peptide count Conﬁdence score Anova (p) Fold change Highest mean condition Lowest mean condition
FGG Fibrinogen gamma chain 4 212 0.0004 4.88 Breast cancer Normal control
FGA Fibrinogen alpha chain 3 177 0.0006 2.26 Breast cancer Normal control
FGB Fibrinogen beta chain 5 350 0.0007 2.75 Breast cancer Normal control
FN1 Fibronectin 7 379 0.0007 3.24 Breast cancer Normal control
APCS Serum amyloid P-component 1 63 0.0017 3.19 Breast cancer Normal control
SERPINC1 Antithrombin-III 1 44 0.0064 2.59 Breast cancer Normal control
C1QA Complement C1q subcomponent subunit A 1 67 0.0066 2.93 Breast cancer Normal control
C4A Complement C4-A 1 84 0.0102 3.91 Breast cancer Normal control
C1QB Complement C1q subcomponent subunit B 1 99 0.0111 3.40 Breast cancer Normal control
C3 Complement C3 5 358 0.0127 3.17 Breast cancer Normal control
CFH Complement factor H 1 47 0.0169 4.03 Breast cancer Normal control
ITIH1 Inter-alpha-trypsin inhibitor heavy chain H1 2 135 0.0170 3.07 Breast cancer Normal control
ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 1 83 0.0201 2.03 Normal control Breast cancer
TTR Transthyretin 1 65 0.0254 3.10 Normal control Breast cancer
F2 Prothrombin 1 58 0.0317 4.07 Normal control Breast cancer
LBP Lipopolysaccharide-binding protein 1 47 0.0336 10.45 Breast cancer Normal control
SERPINF2 Alpha-2-antiplasmin 1 45 0.0350 2.95 Normal control Breast cancer
HBA1 Hemoglobin subunit alpha 1 52 0.0351 9.81 Normal control Breast cancer
ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 1 58 0.0363 4.20 Breast cancer Normal control
CP Ceruloplasmin 1 43 0.0387 2.51 Normal control Breast cancer
APOA1 Apolipoprotein A-I 1 45 0.0413 2.27 Normal control Breast cancer
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Fibrinogen and Fibronectin were selected from the protein list for further
analysis as these twomolecules were determined to be the most statisti-
cally signiﬁcant. CA15-3 was included at this validation stage as a
reference because of the establishedutility this biomarker has in theman-
agement of advanced breast cancer patients. Box-and-whisker plot were
constructed from this ELISA data showing the median and interquartile
range (Fig. 3). Any outliers present in ELISA readings were determined
using Tukey's method which considers values at a distance of 1.5 timesFig. 2. STRING analysis of 21 differentially expressed Transferrin-associated proteins listed in
evidence view uses different-coloured lines to depict the type of evidence that supports each
cascades with the majority of these found to have higher levels in breast cancer patient samplthe interquartile range (IQR) below Q1 (quartile one) or at 1.5 times the
IQR above Q3 (quartile three) to be a possible outlier. Identiﬁed outliers
were subsequently removed from the analysis.
Fibrinogen was discovered to be statistically signiﬁcant when com-
paring control (6.62 μg/ml), inﬂammatory bowel disease (1.98 μg/ml)
and benign breast disease (3.71 μg/ml) to stage IV breast cancer
(14.37 μg/ml). Fibronectin was signiﬁcant when comparing abundance
levels in control samples (235.95 μg/ml) to stage IV breast cancer
(319.08 μg/ml). Similar to Fibrinogen, CA15-3 was statistically signiﬁcantTable 2. The STRING programme generates functional protein association networks. This
interaction. Highlighted in red are proteins involved in the complement and coagulation
es.
Fig. 3. Box and whisker plots (range, median, quartiles) of A. Fibronectin, B. Fibrinogen and C. CA15-3 in control, IBD (Inﬂammatory Bowel Disease), benign breast disease and stages I–IV
breast cancer patient serum samples (validation sample set). Fibrinogen, Fibronectin and CA15-3were all found to be statistically signiﬁcant when comparing abundance levels between
normal control and stage IV breast cancer patient serum samples. Both Fibrinogen and CA15-3 were also statistically signiﬁcant comparing IBD or benign breast disease to stage IV breast
cancer. Samples: normal healthy control (n= 54), inﬂammatory bowel disease (n= 19), benign breast disease (n = 12), stage I breast cancer (n= 20), stage II breast cancer (n= 20),
stage III breast cancer (n = 39) and stage IV breast cancer (n = 76).
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(3.76 IU/ml) and benign breast disease (3.00 IU/ml) to stage IV breast
cancer (18.47 IU/ml)— (see Supplementary information).
Area Under the receiver operator Curve (AUC) value was also calcu-
lated for these three biomarkers and found to be 0.87, 0.72 and 0.93 for
Fibrinogen, Fibronectin and CA15-3 respectively when comparing con-
trol to stage IV breast cancer; 1.0, 0.57 and 0.91 when comparing IBD
to stage IV breast cancer; 0.95, 0.56 and 0.92 when comparing benign
breast disease to stage IV breast cancer. Using logistic regression analy-
sis to investigate the combination of all 3 biomarkers together, AUC-
values of 0.98 (control v stage IV), 1.0 (IBD v stage IV) and 1.0 (benign
breast disease v stage IV) were calculated.4. Discussion
Albumin-bound peptides and proteins can yield important data for
disease diagnosis and management, however, to our knowledge, this
is the ﬁrst investigation focused on identifying Transferrin-bound pep-
tides and proteins as potential biomarkers. Transferrin consists of a
polypeptide chain containing 679 amino acids, with alpha helices and
beta sheets forming two domains. Transferrin is perfectly structured
to perform its primary role of iron transport, although in this investiga-
tion, interactions with other peptides and proteinswere investigated. Af-
ﬁnity resin isolated Transferrin and bound proteins were analysed by
label-free mass spectrometry with 21 differentially expressed proteins
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breast cancer). From this group, Fibrinogen and Fibronectin were select-
ed for further analysis using ELISAs in larger numbers of clinical samples
(normal healthy control (n=54), inﬂammatory bowel disease (n=19),
benign breast disease (n = 12), stage I breast cancer (n = 20), stage II
breast cancer (n = 20), stage III breast cancer (n = 39) and stage IV
breast cancer (n= 76). Both these molecules were found to have signif-
icant alterations in their abundance levels in stage IV breast cancer pa-
tients' serum samples. CA15-3 was also included in the ELISA analysis,
as this is a benchmark biomarker to compare AUC values to.
Fibrinogen and CA15-3 were found to have similar p-values and
AUC-values for distinguishing stage IV breast cancer from the control,
IBD and benign breast disease groups. IBD and benign breast disease
groups (serum samples were from individuals diagnosed with
ﬁbroadenoma of the breast, ﬁbrocystic mastopathy of the breast, ﬁbro-
cystic change with ﬁbroadenoma of the breast, duct papillomas of the
breast or atypical ductal hyperplasia of the breast) were included as
controls for inﬂammation/immunological reactions associated with
cancer at all stages.
Fibronectin was found to be signiﬁcant when comparing just the
control group to stage IV breast cancer. None of these biomarkers
were found to be signiﬁcant when analysing the earlier stage breast
cancer groups and it is evident that only the advanced breast cancer
group was distinguishable from the other groups using these bio-
markers. Using logistic regression analysis to look at the combination
of the 3 biomarkers together, in all three comparisons (control v stage
IV; IBD v stage IV and benign breast disease v stage IV), the panel was
found to bemore accurate in terms of AUC-values as opposed to the in-
dividual values.
Tumour biomarkers are sporadically used in themanagement of pa-
tients with breast cancer, for example for monitoring patients during
therapy for metastatic disease, this molecule may serve as companion
diagnostics to imaging and physical examination. CA15-3 has previous-
ly been found to increase in 75% of breast cancer patients with progres-
sive disease, however with new treatment options available, the ability
to monitor this cohort using reliable protein marker is important [17].
Treatment of metastatic breast cancer has changed with the availability
of new cytotoxics and targeted therapies. This has contributed to a no-
ticeable improvement in both survival and patients' quality of life
[18–20]. Recent data by Hashim demonstrates that higher levels of
CA15-3 could be considered a reliable prognostic biomarker for ad-
vanced stages and recurrent breast cancer as well as being associated
to HER2/neu positivity in breast cancer patients [21].
Reproducible, safe and cost-effective protein-based predictors of
response to these new treatment options are needed to avoid unneces-
sary and toxic therapies and identify suitable regimes. While circulating
tumour cells (CTCs) have shown promise in this area, the ability to
quickly and reliably detect the levels of speciﬁc proteins in patient
blood samples makes this approach attractive over other strategies
[22].
Fibrinogen is a 350-KDa glycoprotein synthesised mainly by liver ep-
ithelium, with an important role in the coagulation system. Fibrinogen is
involved in cancer cell growth, progression andmetastasis, with elevated
levels found in a number of cancer types [23–25]. In this investigation,
Fibrinogen alpha chain, beta chain and gamma chain were all found to
be signiﬁcantly elevated in advanced breast cancer, emphasising its role
in cancer growth and development. Discovery phase analysis identiﬁed
Fibrinogen chains as bound to Transferrin, indicating that many of these
high abundant proteins may form complex with each other in the
blood. Deposits of Fibrinogen in the stroma is considered a hallmark of
breast cancer, and the ability of cancer cells to synthesise and secrete
Fibrinogen may contribute to elevated levels found in the circulation,
especially in patients with a large tumour burden [26].
Fibronectin is a multifunctional, extracellular matrix glycoprotein
composed of two nearly identical disulﬁdebound polypeptides of
molecular weight 220 kDa with functions including cell adhesion, cellmigration and cell proliferation. Elevated levels of Fibronectin have
been reported in patients diagnosed with gastrointestinal or head and
neck cancer [27]. Saito and co-workers found that serum Fibronectin
levels were signiﬁcantly higher in the CRC patients than in the controls
[28]. Williams and colleagues reported ﬁnding supporting a link
betweenﬁbronectin expression and epithelial cell growth during devel-
opment and oncogenesis in the mammary gland [29]. During tumori-
genesis in the breast, primary tumours are characterized by increased
deposition of ﬁbronectin, similar to Fibrinogen, again potentially con-
tributing to elevated circulatory levels [30]. The results presented in
this study show a signiﬁcant increase (~3-fold) in advanced breast
cancer.
A signiﬁcant proportion of the proteins identiﬁed as differentially
expressed from the Transferrin-bound fraction are known to be in-
volved in the complement and coagulation cascades. Cancer cells can
directly secrete procoagulant and tissue factor, thereby activating the
host haemostatic system and also indirectly through the production of
tumour-associated cytokines [31]. Recent ﬁnding that the complement
cascade contributes to tumour growth has generated renewed interest
in this complex area with the possibility of anticomplement strategies
to target cancer cells [32,33]. The elevated level of many complement
and coagulation cascade associated proteins reﬂects the advanced
stage of the disease where most of the tumour speciﬁc processes are
in over-drive.
Venous thromboembolism (VTE) is a major cause of morbidity and
mortality among patients diagnosed with cancer. The risk of VTE is in-
creased by a factor of approximately 6 in patients with cancer compared
with non-cancer patients, with cancer patients contributing 20% of all
newly diagnosed cases of VTE [34–36]. It would be beneﬁcial to identify
biomarkers that would allow for early identiﬁcation of patients at high
or low risk of VTE and consequently the selective use of suitable antico-
agulants. Various established and novel biomarkers associatedwith VTE
have been reported, with ﬁndings in this investigation signifying
derangements in the coagulation cascade that can potentially result in
VTE [37,38].
5. Conclusions
In conclusion, the ﬁndings in this report suggest Transferrin har-
bours many bound proteins that are potentially useful especially in ad-
vanced patient management where more options are now available.
Most of the proteins found and bound to Transferrin are high abundant
molecules themselves, perhaps reﬂecting that such proteins form com-
plexes with each other in the blood. Many of these proteins are associ-
ated with the complement and coagulation systems, areas that have
been the subject of rejuvenated interest of late for potential diagnostic
material and also try to manipulate these cascades from a therapeutic
perspective.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbacli.2014.08.004.
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